We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Five-year survival of patients with disseminated nonseminomatous testicular cancer treated with cisplatin, vinblastine, and bleomycin.
- Authors
Stoter, Gerrit; Vendrik, Cornelis P. J.; Struyvenberg, Albert; Sleyfer, Dirk Th.; Vriesendorp, Rob; Koops, Heimen Schraffordt; van Oosterom, Allan T.; Ten Huinink, Wim W. Bokkel; Pinedo, Herbert M.; Stoter, G; Vendrik, C P; Struyvenberg, A; Sleyfer, D T; Vriesendorp, R; Schraffordt Koops, H; van Oosterom, A T; ten Bokkel Huinink, W W; Pinedo, H M
- Abstract
Ninety-one patients with disseminated testicular non-seminomas were treated with 3 to 4 cycles of cisplatin, vinblastine, and bleomycin (PVB) induction chemotherapy followed by cisplatin and vinblastine maintenance therapy for 1 year. The follow-up of these patients ranges from 24 to 66 months. Forty-nine (54%) patients achieved complete remission by chemotherapy alone and 14 (15%) were rendered free of tumor by surgery after chemotherapy, for a total complete remission rate of 69%. Three complete responders relapsed within 13 months, and two died. One additional complete responder died of a noncancer-related cause. One of the surgical complete responders relapsed and died. Overall, 58 (64%) patients remain free of disease. The 5-year survival is 95% for complete responders, 32% for partial responders, and 72% overall. This combination regimen has significantly improved the survival of disseminated testicular cancer patients, equaling that of Stage II patients in older literature.
- Publication
Cancer (0008543X), 1984, Vol 54, Issue 8, p1521
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19841015)54:8<1521::AID-CNCR2820540808>3.0.CO;2-8